Law360, New York (May 04, 2012, 5:26 PM ET) -- A U.S. Food and Drug Administration advisory panel should consider whether the apparent effectiveness of a Regeneron Pharmaceuticals Inc. gout treatment outweighs the increased risk of cancer it may bring, agency researchers said in advance of a meeting Tuesday.
An arthritis advisory committee is gathering to provide recommendations to the FDA regarding the use of the drug Arcalyst to treat gout flares. Arcalyst is already approved to treat two rare genetic disorders, familial cold auto-inflammatory syndrome and cryopyrin-associated periodic syndromes, or CAPS.
In background information released...
FDA Panel To Find If Regeneron Gout Drug's Risks Too High
To view the full article, take a free trial now.
